Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

. . . . . . . . . . . . . . . . . . . . Good morning, ladies and gentlemen. Thank you for standing by and welcome. At this time, all participants are in listening mode, and following the presentation, we will conduct a question and answer session. Please be advised that today's call may be recorded. I would now like to hand the call over to Anne Marie Fields, Managing Director of PrecisionAQ. Please go ahead. Thank you, operator. Good morning, and welcome to Selectar Biosciences' second quarter 2026 financial results and business update conference call. Joining us today from Selectar are Jim Caruso, President and CEO, who will provide an overview of the company's progress, before turning the call over to Chad Kolean, CFO, for a financial review of the quarter. Following this, Jarrod Longcor, Chief Operating Officer, will give an update on the company's progress and plans for its promising clinical development pipeline of radiopharmaceuticals. Selectar issued a press release earlier this morning detailing the content of today's call. Copy can be found on the investor page of the Selectar's corporate website. I want to remind callers that the information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. I caution listeners that management will be making forward-looking statements. Actual results could differ materially from those stated or implied by our forward-looking statements due to risks and uncertainties associated with the business. These forward-looking statements are qualified in their entirety by the cautionary statements contained in today's press release and in our FEC filing. The content of this conference call contains time-sensitive information. that is accurate only as of the date o...